Reykjavik (IFN) Icelandic gerneric drug maker Actavis Group has launched five new products in the United States, all of which will be marketed under the company's own label, the company said on Wednesday.
"These product launches lend additional support to our growing portfolio in the US market and are a further demonstration of the strength of our broad pipeline," said Sigurdur Oli Olafsson, head of Actavis North American operations.
"We have had a strong first half of the year and expect to launch a total of 15 generic products during 2006, which will drive our growth in this important market. We also remain on course to file at least 30 new ANDAs this year," Olafsson added.
The five products include Dantrolene, a generic product to treat chronic spasticity and malignant hypothermia and Isradipine, a generic product for the treatment of hypertension.
Amantadine, a generic product to treat symptoms of influenza A virus and Dipyridamole, a generic product to reduce the risk of blood clots after heart valve replacement are also among the new products.
Actavis is currently in a bidding war against US-based Barr Pharmaceuticals to acquire Croatian rival Pliva, but both firms have tabled informal bids in the region of USD2.3 billion and filed intentions with local authorities to put in formal offers.
(END)
Icelandic Financial News (IFN) is available on Factiva, a joint venture between Reuters and Dow Jones Newswires, FT.COM, LexisNexis, Comtex, Gale and Thomson via the Nordic Business Report.
